BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 34001679)

  • 41. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of an individualized RNA binding protein-based prognostic signature for diffuse large B-cell lymphoma.
    Xie Y; Luo X; He H; Pan T; He Y
    Cancer Med; 2021 Apr; 10(8):2703-2713. PubMed ID: 33749163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma.
    Zhou F; Chen L; Lu P; Cao Y; Deng C; Liu G
    BMC Cancer; 2023 Jul; 23(1):641. PubMed ID: 37430195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gene expression profiles analysis identifies a novel two-gene signature to predict overall survival in diffuse large B-cell lymphoma.
    Sun C; Cheng X; Wang C; Wang X; Xia B; Zhang Y
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30393234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma.
    Huang Q; Liu F; Shen J
    Per Med; 2019 Jul; 16(4):313-323. PubMed ID: 31331250
    [No Abstract]   [Full Text] [Related]  

  • 46. USP21 promotes cell proliferation by maintaining the EZH2 level in diffuse large B-cell lymphoma.
    Ma H; Luo X; Zhou P; He N; Zhou J; Liu M; Xie W
    J Clin Lab Anal; 2021 Mar; 35(3):e23693. PubMed ID: 33389794
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
    Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
    Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.
    Ma J; Yan S; Zhao Y; Yan H; Zhang Q; Li X
    Front Immunol; 2023; 14():1265255. PubMed ID: 37841254
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
    Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
    BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ferroptosis Markers Predict the Survival, Immune Infiltration, and Ibrutinib Resistance of Diffuse Large B cell Lymphoma.
    Weng J; Chen L; Liu H; Yang XP; Huang L
    Inflammation; 2022 Jun; 45(3):1146-1161. PubMed ID: 35064379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
    Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
    Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
    [TBL] [Abstract][Full Text] [Related]  

  • 53. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
    Bedekovics T; Hussain S; Feldman AL; Galardy PJ
    Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.
    Schuhmacher B; Rengstl B; Döring C; Bein J; Newrzela S; Brunnberg U; Kvasnicka HM; Vornanen M; Küppers R; Hansmann ML; Hartmann S
    Oncotarget; 2016 Nov; 7(44):72197-72210. PubMed ID: 27708232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression and clinical significance of ubiquitin‑specific‑processing protease 34 in diffuse large B‑cell lymphoma.
    Li C; Huang L; Lu H; Wang W; Chen G; Gu Y; Zhou Q; Peng Z; Feng Z
    Mol Med Rep; 2018 Nov; 18(5):4543-4554. PubMed ID: 30221700
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
    Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T
    Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of survival of diffuse large B-cell lymphoma patients via the expression of three inflammatory genes.
    Zhao S; Bai N; Cui J; Xiang R; Li N
    Cancer Med; 2016 Aug; 5(8):1950-61. PubMed ID: 27394196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B-cell lymphoma cells and their association with clinical features.
    Kobayashi K; Yamaguchi M; Miyazaki K; Imai H; Yokoe K; Ono R; Nosaka T; Katayama N
    Cancer Med; 2016 Aug; 5(8):1802-9. PubMed ID: 27184832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.